GENT Stock Overview
Researches, develops, and produces biochemical reagents for use in medical diagnostics and research worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Gentian Diagnostics ASA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr42.80 |
| 52 Week High | kr49.20 |
| 52 Week Low | kr34.80 |
| Beta | 0.59 |
| 1 Month Change | 10.88% |
| 3 Month Change | 7.27% |
| 1 Year Change | -6.96% |
| 3 Year Change | -17.37% |
| 5 Year Change | -15.75% |
| Change since IPO | 64.62% |
Recent News & Updates
Recent updates
Analyst Estimates: Here's What Brokers Think Of Gentian Diagnostics ASA (OB:GENT) After Its Annual Report
Feb 14
Here's Why We're Not At All Concerned With Gentian Diagnostics' (OB:GENT) Cash Burn Situation
Oct 28We're Not Worried About Gentian Diagnostics' (OB:GENT) Cash Burn
May 11Can You Imagine How Gentian Diagnostics' (OB:GENT) Shareholders Feel About The 57% Share Price Increase?
Mar 20What Percentage Of Gentian Diagnostics AS (OB:GENT) Shares Do Insiders Own?
Feb 21Have Insiders Been Selling Gentian Diagnostics AS (OB:GENT) Shares?
Jan 17
Gentian Diagnostics AS (OB:GENT): When Will It Breakeven?
Dec 14Shareholder Returns
| GENT | NO Medical Equipment | NO Market | |
|---|---|---|---|
| 7D | 6.5% | -1.1% | 0.6% |
| 1Y | -7.0% | 6.5% | 8.0% |
Return vs Industry: GENT underperformed the Norwegian Medical Equipment industry which returned 6.5% over the past year.
Return vs Market: GENT underperformed the Norwegian Market which returned 8% over the past year.
Price Volatility
| GENT volatility | |
|---|---|
| GENT Average Weekly Movement | 5.2% |
| Medical Equipment Industry Average Movement | 5.6% |
| Market Average Movement | 5.0% |
| 10% most volatile stocks in NO Market | 10.8% |
| 10% least volatile stocks in NO Market | 3.1% |
Stable Share Price: GENT has not had significant price volatility in the past 3 months.
Volatility Over Time: GENT's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 58 | Njaal Kind | www.gentian.com |
Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research worldwide. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric immunoassay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a glomerular filtration rate marker for the diagnosis and therapeutic control of renal function; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and canine CRP immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. It also provides SARS-CoV-2 total antibody immunoassay, quantitative antibody test captures the full immune response detecting antibodies targeting the S1-subunit.
Gentian Diagnostics ASA Fundamentals Summary
| GENT fundamental statistics | |
|---|---|
| Market cap | kr660.08m |
| Earnings (TTM) | -kr5.83m |
| Revenue (TTM) | kr149.41m |
4.4x
P/S Ratio-113.2x
P/E RatioIs GENT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GENT income statement (TTM) | |
|---|---|
| Revenue | kr149.41m |
| Cost of Revenue | kr68.88m |
| Gross Profit | kr80.53m |
| Other Expenses | kr86.37m |
| Earnings | -kr5.83m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 29, 2024
| Earnings per share (EPS) | -0.38 |
| Gross Margin | 53.90% |
| Net Profit Margin | -3.90% |
| Debt/Equity Ratio | 0% |
How did GENT perform over the long term?
See historical performance and comparison